Key result
Systematic review compares DES, DCBs, and alternative strategies for treating in-stent restenosis.
Why the study?
Management of patients with in-stent restenosis remains an important clinical problem, and treatment of drug-eluting stent ISR is particularly challenging.
What are the current therapeutic modalities and their efficacy for treating in-stent restenosis?
Systematic Review
What are the current therapeutic modalities and their efficacy for treating in-stent restenosis?
This systematic review summarizes current therapeutic modalities, including drug-eluting stents and drug-coated balloons, for the management of in-stent restenosis.
Answers are grounded in this paper and cite their sources.
Clinicians should integrate intracoronary imaging to guide DES or DCB use in ISR; leaves open optimal combination therapies pending further trials.
Management of patients with in-stent restenosis (ISR) remains an important clinical problem. Although drug-eluting stents (DES) have drastically reduced the incidence of ISR, treatment of DES-ISR is particularly challenging. ISR mainly results from aggressive neointimal proliferation, but recent data also suggest that neoatherosclerosis may play an important pathophysiological role. Intracoronary imaging provides unique insights to unravel the underlying substrate of ISR and may be used to guide repeated interventions. In this paper, we systematically reviewed clinical trial data with currently available therapeutic modalities, including DES and drug-coated balloons, in patients presenting with ISR within bare-metal stents or DES.
No takes yet. Share an insight, caveat, or question.
Alfonso et al. (2014) conducted a systematic review in In-stent restenosis. Drug-eluting stents and drug-coated balloons was evaluated. A systematic review evaluated currently available therapeutic modalities, including drug-eluting stents and drug-coated balloons, for the treatment of in-stent restenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: